Product Description: Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research[1][2][3][4].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Hannah A Blair, et al. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs. 2018 Mar;78(3):355-366./[2]Stohl W, et al. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012 Jan 9;30(1):69-77./[3]Halpern WG, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006 Jun;91(2):586-99.
CAS Number: 356547-88-1
Molecular Weight: N/A
Compound Purity: 99.40
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: CD20;TNF Receptor
English
Deutsch
